medigraphic.com
ISSN 1561-302X (Impreso)

2021, Número 1

<< Anterior Siguiente >>

Rev cubana med 2021; 60 (1)


Nuevos aspectos moleculares y fisiopatológicos de la anemia drepanocítica

Soler NG, Escalona MLZ, Peña LK

Idioma: Español
Referencias bibliográficas: 29
Paginas: 1-10
Archivo PDF: 434.23 Kb.


RESUMEN

Introducción: La enfermedad por hemoglobina S es una anemia hemolítica crónica hereditaria cuyas manifestaciones clínicas provienen de la tendencia de esta hemoglobina de polimerizar y deformar los eritrocitos dándoles la típica forma de media luna, platanito, drepanocitos o "sickle cell"; de aquí el nombre de anemia drepanocítica o sicklemia.
Objetivo: Describir los nuevos aspectos moleculares, fisiopatológicos y el diagnóstico de la anemia drepanocítica.
Métodos: Se realizó una revisión de la literatura, en inglés y español, a través del sitio web PubMed y el motor de búsqueda Google académico de artículos publicados en los últimos 10 años. Se hizo un análisis y resumen de la bibliografía revisada.
Conclusiones: La comprensión de la complejidad y multiplicidad de eventos que conducen a complicaciones graves en la anemia drepanocítica y nuestra incapacidad para predecir el curso clínico en cada caso particular ayudaría en la prevención de estos eventos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle celldisease. Nature Reviews Disease Primers. 2018;4:18010.

  2. Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing globalhealth importance. Arch Dis Child. 2015;100:48-53. http://doi.org/10.1136/archdischild-2013-303773

  3. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN. et al. Global distribution ofthe sickle cell gene and geographical confirmation of the malaria hypothesis. Naturecommunications. 2010;1:104. http://doi.org/:10.1038/ncomms1104

  4. Kato GJ. New Insights into Sickle Cell Disease: Mechanisms and Investigational Therapies.Current opinion in hematology. 2016;23(3):224-32.http://doi.org/10.1097/MOH.0000000000000241

  5. Das R, Mitra A, Mitra G, Maity D, Bhat V, Pal D, et al. Molecular insights of inhibition in sicklehemoglobin polymerization upon glutathionylation: hydrogen/deuterium exchange massspectrometry and molecular dynamics simulation based approach. Biochemical Journal. 2018;BCJ20180306. http://doi.org/10.1042/BCJ20180306

  6. Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017;blood-2017-02-765891. http://doi.org/10.1182/blood-2017-02-765891

  7. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376:1561-73.http://doi.org/10.1056/NEJMra1510865

  8. Esin Al, Bergendah lLT, Savolainen V, Marsh J, Warnecke T. The genetic basis and evolution ofred blood cell sickling in deer. Nature Ecology & Evolution. 2018;2:367-76.http://doi.org/10.1038/s41559-017-0420-3

  9. Garneau AP, Marcoux AA, Frenette-Cotton R, Mac-Way F, Lavoie JL, Isenring P. Molecularinsights into the normal operation, regulation, and multisystemic roles of K+-Cl−cotransporter 3 (KCC3). American Journal of Physiology. 2017;3131(5):516-32.http://doi.org/10.1152/ajpcell.00106.2017

  10. Postgraduate Haematology, FifthEdition. Edited by A. Victor Hoffbrand, Daniel Catovsky,Edward G.D. Tuddenham. Copyright © 2005 Blackwell Publishing Ltd, 9600 Garsington Road,Oxford OX4 2DQ, UK.

  11. Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, et al. A Multinational Trial ofPrasugrel for Sickle Cell Vaso-Occlusive Events. New England Journal of Medicine. 2016[acceso:15/05/2020];374(7):625-35. Disponible en:https://www.nejm.org/doi/full/10.1056/NEJMoa1512021

  12. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sicklecell disease. J Clin Invest. 2017;127(3):750-60. http://doi.org/10.1172/JCI89741

  13. Nayar S, Acharya S, Acharya R, Kishore S, Thakur B. Spectrum of Haemoglobinopathies: AHospital Based Study in Uttarakhand. Journal Of Clinical & Diagnostic Research. 2017;11(12):18-21. http://doi.org/10.7860/JCDR/2017/31731.10947

  14. Garnier Y, Ferdinand S, Etienne-Julan M, Elana G, Petras M, Doumdo L, et al. Differences ofmicroparticle patterns between sickle cell anemia and hemoglobin SC patients. PLoS ONE.2017;12(5):0177397. http://doi.org/10.1371/journal.pone.0177397

  15. Lin MI, Paik E, Mishra B, Burkhardt D, Kernytsky A, Pettiglio M, et al. CRISPR/Cas9 GenomeEditing to Treat Sickle Cell Disease and B-Thalassemia: Re-Creating Genetic Variants to UpregulateFetal Hemoglobin Appear Well-Tolerated, Effective and Durable. Blood. 2017[acceso:15/05/2020];130(S1):284. Disponible en: http://www.bloodjournal.org/content/130/Suppl_1/284

  16. Opi DH, Ochola LB, Tendwa M, Siddondo BR, Ocholla H, Fanjo H, et al. Mechanistic studies ofthe negative epistatic malaria-protective interation between sickle cell trait and α+thalasaemia.EBio Medicine. 2014;1(1):29-36. http://doi.org/10.1016/j.ebiom.2014.10.006

  17. Rivera-Paz EE, Espinal-Palacios AG, Palencia EP, Hernández AP. Anemia de células falciformescon persistencia de hemoglobina fetal como factor protector: reporte de caso. Rev Mex Pediatr.2016;82(2):55-9.

  18. Lin MI, Paik EJ, Mishra BP, Chou S, Zhang Y, Tomkinson K, et al. Re-Creating HereditaryPersistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia.Blood. 2016[acceso: 15/05/2020];128(22):4708. Disponible en:http://www.bloodjournal.org/content/128/22/4708

  19. Paglietti ME, Satta S, Sollaino MC, Barella S, Ventrella A, Desogus MF, et al. The Problem ofBorderline Hemoglobin A2 Levels in the Screening for β-Thalassemia Carriers in Sardinia. ActaHaematol. 2016;135:193-9.

  20. Italia K, Upadhye D, Dabke P, Kangane H, Colaco S, Sawant P, et al. Clinical and hematologicalpresentation among indian patients with common hemoglobin variants. Clinica Quimica Acta.2014;431:46-51. http://doi.org/10.1016/j.cca.2014.01.028

  21. Bezirgiannidou Z, Christoforidou A, Kontekaki E, Anastasiadis AG, Papamichos SI, Menexidou H,et al. Hyperhemolytic Syndrome Complicating a Delayed Hemolytic Transfusion Reaction due toanti-P1 Alloimmunization, in a Pregnant Woman with HbO-Arab/β-Thalassemia. MediterraneanJournal of Hematology and Infectious Diseases. 2016;8(1):e2016053.http://doi.org/10.4084/MJHID.2016.053

  22. Chotivanich K, Udomsangpetch R, Pattanapanyasat K, Chierakul W, Simpson J, LooareesuwanS, et al. Hemoglobin E: a balanced polymorphism protective against high parasitemias and thussevere P. falciparum malaria. Blood. 2002[acceso: 15/05/2020];100(4):1172-6. Disponible en:http://www.bloodjournal.org/content/100/4/1172

  23. Erramouspe B, Eandi Eberle SJ. Conventional techniques applied to the diagnosis ofhemoglobinopathies. Acta bioquím clín latinoam. 2017[acceso: 15/05/2020];51(3):325-32.Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-29572017000300007&lng=es

  24. Noubouossie D, NS Key, Ataga KI. Coagulation abnormalities of sickle cell disease: Relationshipwith clinical outcomes and the effect of disease modifying therapies. Blood Review.2016;30(4):245-56. http://doi.org/10.1016/j.blre.2015.12.003

  25. Yoon CS, Tan YM, Law HY. AB091. Comparison of two haemoglobin electrophoresis platformsfor the detection of haemoglobinopathies. Annals of Translational Medicine. 2017;5(S2):AB091.http://doi.org/10.21037/atm.2017.s091

  26. Begum K, Mannan MA, Sanyal M, Hosen I, Chakraborty S, Shekhar H. Molecular DiagnosticApproach Prevails Superior Over Conventional Gel-Electrophoresis Method in Detecting Sickle CellAnemia. J Mol Biomark Diagn. 2018;9:382. http://doi.org/10.4172/2155-9929.1000382

  27. McGann PT, Hoppe C. The pressing need for point-of-care diagnostic for sickle cell disease: Areview of current and future technologies. Blood Cells Molecules and Diseases. 2017;67:104-13.http://doi.org/10.1016/j.bcmd.2017.08.010

  28. Traeger-Synodinos J, Harteveld CL, Old JM, Petrou M, Galanello R, Giordano P, et al. EMQNBest Practice Guidelines for molecular and haematology methods for carrier identification andprenatal diagnosis of the haemoglobinopathies. European Journal of Human Genetics.2015;23:426-37. http://doi.org/10.1038/ejhg.2014.131

  29. Camilo-Araújo RF, Silverio Amancio OM, Figueiredo MS, Cabanãs-Pedro AC, Pellegrini Braga JA.Molecular analysis and association with clinical and laboratory manifestations in children withsickle cell anemia. Rev Bras Hematol Hemoter. 2014;36(5): 334-9.http://doi.org/10.1016/j.bjhh.2014.06.002




2020     |     www.medigraphic.com